Biostage, Inc. announced that effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately, and also amend certain terms of Mr. Green's existing Employment Agreement.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | +3.02% | +3.02% | -52.10% |
1st Jan change | Capi. | |
---|---|---|
-52.10% | 34.21M | |
+7.15% | 220B | |
+6.60% | 183B | |
+9.86% | 133B | |
+24.32% | 107B | |
-0.95% | 63.05B | |
+11.04% | 51.74B | |
+4.81% | 50.47B | |
-1.43% | 40.91B | |
+24.40% | 31.91B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Amends CEO Employment Agreement